Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy C Sherman

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Vaccine|October 17, 2024
Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adultsVarun K Phadke, Daniel J Gromer, Paulina A Rebolledo, et al.
Iscience|November 21, 2024
The BNT162b2 mRNA vaccine demonstrates reduced age-associated T<sub>H</sub>1 support <i>in vitro</i> and <i>in vivo</i>Byron Brook, Abhinav Kumar Checkervarty, Soumik Barman, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in salivaPranay R Randad, Nora Pisanic, Kate Kruczynski, et al.
The Lancet. Infectious Diseases|January 10, 2026
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trialDeborah R Leitner, Stephen R Walsh, Masataka Suzuki, et al.
Research Square|January 4, 2023
The mRNA vaccine BNT162b2 demonstrates impaired T<sub>H</sub>1 immunogenicity in human elders <i>in vitro</i> and aged mice <i>in vivo</i>Byron Brook, Benoit Fatou, Abhinav Kumar Checkervarty, et al.
Journal of Clinical Microbiology|October 17, 2020
COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in SalivaNora Pisanic, Pranay R Randad, Kate Kruczynski, et al.
Immunity|May 9, 2025
Computationally designed proteins mimic antibody immune evasion in viral evolutionNoor Youssef, Sarah Gurev, Fadi Ghantous, et al.
Frontiers in Public Health|December 10, 2021
Application of SARS-CoV-2 Serology to Address Public Health PrioritiesAmy C Sherman, Teresa Smith, Yerun Zhu, et al.
Vaccine|November 30, 2025
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccinationSharon E Frey, Lindsey R Baden, Hana M El Sahly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 28, 2025
Comparative Outcomes of Babesiosis in Immunocompromised and Non-Immunocompromised Hosts: A Multicenter Cohort StudyLoukas Kakoullis, Carolyn D Alonso, Rebecca Burns, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Vaccine|October 17, 2024
Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adultsVarun K Phadke, Daniel J Gromer, Paulina A Rebolledo, et al.
Iscience|November 21, 2024
The BNT162b2 mRNA vaccine demonstrates reduced age-associated T<sub>H</sub>1 support <i>in vitro</i> and <i>in vivo</i>Byron Brook, Abhinav Kumar Checkervarty, Soumik Barman, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in salivaPranay R Randad, Nora Pisanic, Kate Kruczynski, et al.
The Lancet. Infectious Diseases|January 10, 2026
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trialDeborah R Leitner, Stephen R Walsh, Masataka Suzuki, et al.
Research Square|January 4, 2023
The mRNA vaccine BNT162b2 demonstrates impaired T<sub>H</sub>1 immunogenicity in human elders <i>in vitro</i> and aged mice <i>in vivo</i>Byron Brook, Benoit Fatou, Abhinav Kumar Checkervarty, et al.
Journal of Clinical Microbiology|October 17, 2020
COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in SalivaNora Pisanic, Pranay R Randad, Kate Kruczynski, et al.
Immunity|May 9, 2025
Computationally designed proteins mimic antibody immune evasion in viral evolutionNoor Youssef, Sarah Gurev, Fadi Ghantous, et al.
Frontiers in Public Health|December 10, 2021
Application of SARS-CoV-2 Serology to Address Public Health PrioritiesAmy C Sherman, Teresa Smith, Yerun Zhu, et al.
Vaccine|November 30, 2025
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccinationSharon E Frey, Lindsey R Baden, Hana M El Sahly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 28, 2025
Comparative Outcomes of Babesiosis in Immunocompromised and Non-Immunocompromised Hosts: A Multicenter Cohort StudyLoukas Kakoullis, Carolyn D Alonso, Rebecca Burns, et al.
Pageof 6